Leerink Partners Upgrades ARS Pharmaceuticals to Outperform, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Roanna Ruiz upgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Market Perform to Outperform and raises the price target from $6 to $18.
March 05, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners upgraded ARS Pharmaceuticals to Outperform and increased the price target to $18.
The upgrade from Market Perform to Outperform by a reputable analyst, along with a significant increase in the price target, suggests a strong bullish outlook for ARS Pharmaceuticals. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100